Skip to main content
Mary Disis, MD, Oncology, Seattle, WA, Seattle Children's Hospital

MaryLenoraDisisMD

Oncology Seattle, WA

Associate Professor of Medicine, University Wash

Dr. Disis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Disis' full profile

Already have an account?

Education & Training

  • University of Washington
    University of WashingtonFellowship, Hematology and Medical Oncology, 1990 - 1993
  • University of Nebraska College of Medicine
    University of Nebraska College of MedicineClass of 1986

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 1990 - 2025
  • IL State Medical License
    IL State Medical License 1986 - 1990
  • American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Oncology and COVID-19 
    International Society for Biological Therapy of Cancer (iSBTc)/ Society for Immunotherapy of Cancer, - 10/24/2012

Press Mentions

  • Cancer Vaccines Could Soon Become a Reality
    Cancer Vaccines Could Soon Become a RealityJanuary 3rd, 2023
  • Moderna, Merck Cancer Vaccine Combo Cuts Melanoma Recurrence by 44%
    Moderna, Merck Cancer Vaccine Combo Cuts Melanoma Recurrence by 44%December 13th, 2022
  • Modern Positive, Merck Cancer Vaccine Data Advances mRNA Promise, Stocks Rise
    Modern Positive, Merck Cancer Vaccine Data Advances mRNA Promise, Stocks RiseDecember 13th, 2022
  • Join now to see all

Grant Support

  • CTSA Infrastructure For Pediatric Clinical TrialsNational Center For Research Resources2010–2011
  • Bastyr/Uw Oncomycology Translational Research CenterNational Center For Complementary &Alternative Medicine2010–2011
  • Vaccinating Against IGFBP-2 To Prevent Ovarian Cancer RelapseNational Cancer Institute2009–2011
  • Immune Diagnostics And Vaccine Targets: Breast Cancer Antigens From Mice To WomenNational Cancer Institute2009–2011
  • Institute For Translational Health Science (KL2)National Center For Research Resources2008–2011
  • CTSA Infrastructure For Pediatric ResearchNational Center For Research Resources2008–2011
  • CTSA Infrastructure For Clinical TrialsNational Center For Research Resources2008–2011
  • CTSA Infrastructure For AIDS ResearchNational Center For Research Resources2008–2011
  • Adoptive T Cell Therapy For The Treatment Of HER2 Overexpressing CancersNational Cancer Institute2008–2011
  • Institute For Translational Health Science (UL1)National Center For Research Resources2007–2011
  • Institute For Translational Health Science (TL1)National Center For Research Resources2007–2011
  • Optimized Ex Vivo Expansion Of Anti-Tumor TH1 And TC1 For Adoptive Immunotherapy.National Cancer Institute2009–2010
  • Mechanisms Of Immunomodulatory And Anti-Tumor Actions Of Polysaccharide KrestinNational Center For Complementary &Alternative Medicine2007–2010
  • Institute For Translational Health Science (Ul1): BpcaNational Center For Research Resources2009
  • Institute For Translational Health ScienceNational Center For Research Resources2008–2009
  • Phase II Study Of A Her-2/Neu Intracellular Domain (ICD) Peptide-Based VaccineNational Center For Research Resources2007
  • Novel Methold Of Immunologic Monitoring For Assessing Cancer ImmunotherapiesNational Center For Research Resources2007
  • Institute For Translational Health Science Pediatric ResearchNational Center For Research Resources2007
  • Institute For Translational Health Science For Clinical TrialsNational Center For Research Resources2007
  • Institute For Translational Health Science For AIDS ResearchNational Center For Research Resources2007
  • Institute For Translational Health ScienceNational Center For Research Resources2007
  • Safety And Immunogenicity Study Of DNA Plasmid Based Vaccine For TumorsNational Center For Research Resources2005–2007
  • Phase I-II Study Of Combination Immunotherapy For Her-2/Neu Cytotoxic T CellsNational Center For Research Resources2004–2007
  • Phase I Trial Of A HER2 ICD Plasmid-Based DNA VaccineNational Cancer Institute2003–2007
  • Multi-Antigen Vaccines For Breast CancerNational Cancer Institute2003–2007
  • Planning Grant For Institutional Clinical And Translational Science AwardNational Center For Research Resources2006
  • A Feasibility Study Of Ex Vivo Expansion And Infusion Of HER2 T CellsNational Center For Research Resources2006
  • Novel Methods Of Immunologic Monitoring For Assessing Cancer ImmunotherapiesNational Center For Research Resources2004–2006
  • Immunologic Correlates Of Immunization For CancerNational Cancer Institute2001–2006
  • Midcareer Investigator Award In Patient Oriented ResearcNational Cancer Institute2000–2004
  • HER2 Vaccination For The Treatment Of CancerNational Cancer Institute2000–2004
  • Antibodies As A Marker Of Effective ImmunizationNational Cancer Institute2001–2002
  • H2n Peptide Vaccine In PTS With H2n Expressing CancerNational Center For Research Resources2000–2002
  • Study Of A H2n Peptide Vaccine In Patients With Advanced H2n Expressing CancersNational Center For Research Resources1997–2000
  • H2n Peptide Vaccines--Patients Wi/H2n Expressing CancersNational Cancer Institute1997–1999
  • T Cell Immunity To Human Breast CancerNational Cancer Institute1995–1999
  • Evaluation Of Immunity To Her-2/Neu In A Rodent ModelNational Cancer Institute1995–1999

Hospital Affiliations